<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines
<p>Abstract</p> <p>Background</p> <p>Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect of a novel NO-releasing derivate, NCX 4040, with that of aspi...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2005-02-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/3/1/7 |
id |
doaj-289f409d635d4b20aa9929521173cec4 |
---|---|
record_format |
Article |
spelling |
doaj-289f409d635d4b20aa9929521173cec42020-11-25T00:26:16ZengBMCJournal of Translational Medicine1479-58762005-02-0131710.1186/1479-5876-3-7<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell linesZupi GabriellaScarsella MarcoLeonetti CarloRosetti MarcoFabbri FrancescoUlivi PaolaTesei AnnaAmadori DinoBolla ManlioZoli Wainer<p>Abstract</p> <p>Background</p> <p>Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect of a novel NO-releasing derivate, NCX 4040, with that of aspirin and its denitrated analog, NCX 4042, in <it>in vitro </it>and <it>in vivo </it>human colon cancer models and investigated the mechanisms of action underlying its antitumor activity.</p> <p>Methods</p> <p><it>In vitro </it>cytotoxicity was evaluated on a panel of colon cancer lines (LoVo, LoVo Dx, WiDr and LRWZ) by sulforhodamine B assay. Cell cycle perturbations and apoptosis were evaluated by flow cytometry. Protein expression was detected by Western blot. In the <it>in vivo </it>experiments, tumor-bearing mice were treated with NCX 4040, five times a week, for six consecutive weeks.</p> <p>Results</p> <p>In the <it>in vitro </it>studies, aspirin and NCX 4042 did not induce an effect on any of the cell lines, whereas NCX 4040 produced a marked cytostatic dose-related effect, indicating a pivotal role of the -NO<sub>2 </sub>group. Furthermore, in LoVo and LRWZ cell lines, we observed caspase-9 and -3-mediated apoptosis, whereas no apoptotic effect was observed after drug exposure in WiDr or LoVo Dx cell lines. In <it>in vivo </it>studies, both NCX 4040 and its parental compound were administered <it>per os</it>. NCX 4040 induced a 40% reduction in tumor weight. Conversely, aspirin did not influence tumor growth at all.</p> <p>Conclusions</p> <p>NCX 4040, but not its parental compound, aspirin, showed an <it>in vitro </it>and <it>in vivo </it>antiproliferative activity, indicating its potential usefulness to treat colon cancer.</p> http://www.translational-medicine.com/content/3/1/7 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zupi Gabriella Scarsella Marco Leonetti Carlo Rosetti Marco Fabbri Francesco Ulivi Paola Tesei Anna Amadori Dino Bolla Manlio Zoli Wainer |
spellingShingle |
Zupi Gabriella Scarsella Marco Leonetti Carlo Rosetti Marco Fabbri Francesco Ulivi Paola Tesei Anna Amadori Dino Bolla Manlio Zoli Wainer <it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines Journal of Translational Medicine |
author_facet |
Zupi Gabriella Scarsella Marco Leonetti Carlo Rosetti Marco Fabbri Francesco Ulivi Paola Tesei Anna Amadori Dino Bolla Manlio Zoli Wainer |
author_sort |
Zupi Gabriella |
title |
<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines |
title_short |
<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines |
title_full |
<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines |
title_fullStr |
<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines |
title_full_unstemmed |
<it>In vitro </it>and <it>in vivo </it>evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines |
title_sort |
<it>in vitro </it>and <it>in vivo </it>evaluation of ncx 4040 cytotoxic activity in human colon cancer cell lines |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2005-02-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect of a novel NO-releasing derivate, NCX 4040, with that of aspirin and its denitrated analog, NCX 4042, in <it>in vitro </it>and <it>in vivo </it>human colon cancer models and investigated the mechanisms of action underlying its antitumor activity.</p> <p>Methods</p> <p><it>In vitro </it>cytotoxicity was evaluated on a panel of colon cancer lines (LoVo, LoVo Dx, WiDr and LRWZ) by sulforhodamine B assay. Cell cycle perturbations and apoptosis were evaluated by flow cytometry. Protein expression was detected by Western blot. In the <it>in vivo </it>experiments, tumor-bearing mice were treated with NCX 4040, five times a week, for six consecutive weeks.</p> <p>Results</p> <p>In the <it>in vitro </it>studies, aspirin and NCX 4042 did not induce an effect on any of the cell lines, whereas NCX 4040 produced a marked cytostatic dose-related effect, indicating a pivotal role of the -NO<sub>2 </sub>group. Furthermore, in LoVo and LRWZ cell lines, we observed caspase-9 and -3-mediated apoptosis, whereas no apoptotic effect was observed after drug exposure in WiDr or LoVo Dx cell lines. In <it>in vivo </it>studies, both NCX 4040 and its parental compound were administered <it>per os</it>. NCX 4040 induced a 40% reduction in tumor weight. Conversely, aspirin did not influence tumor growth at all.</p> <p>Conclusions</p> <p>NCX 4040, but not its parental compound, aspirin, showed an <it>in vitro </it>and <it>in vivo </it>antiproliferative activity, indicating its potential usefulness to treat colon cancer.</p> |
url |
http://www.translational-medicine.com/content/3/1/7 |
work_keys_str_mv |
AT zupigabriella itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT scarsellamarco itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT leonetticarlo itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT rosettimarco itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT fabbrifrancesco itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT ulivipaola itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT teseianna itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT amadoridino itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT bollamanlio itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines AT zoliwainer itinvitroitanditinvivoitevaluationofncx4040cytotoxicactivityinhumancoloncancercelllines |
_version_ |
1725345112295211008 |